Global HIV Drugs Market Research Report 2023-2031: Antiretroviral Therapy (ART) Emerging as Pivotal Tool in Managing HIV and Enhancing Well-Being

Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The "Global HIV Drugs Market Report and Forecast 2023-2031" report has been added to's offering.

The global HIV drugs market value was USD 32.1 billion in 2022, driven by the increasing prevalence of HIV across the globe. The market size is anticipated to grow at a CAGR of 4.5% during the forecast period of 2023-2031 to achieve a value of USD 47.8 billion by 2031.

HIV drugs, particularly antiretroviral therapy (ART), have emerged as pivotal tools in managing HIV and enhancing the well-being of individuals affected by the virus. ART encompasses a combination of medications designed to collaboratively suppress the virus, thwart its progression to Acquired Immune Deficiency Syndrome (AIDS), and diminish the risk of transmission.

In recent times, the global HIV drugs market has undergone substantial expansion, driven by various factors. These include the escalating prevalence of HIV, remarkable strides in antiretroviral therapy, the emergence of novel treatment regimens, and a concerted effort to widen treatment accessibility in low- and middle-income nations. Additionally, the market's growth is propelled by an escalating demand for innovative therapies renowned for their superior efficacy, reduced side effects, and enhanced patient adherence when compared to conventional treatments.

The adoption of HIV drugs has experienced consistent growth due to the enduring prevalence of HIV and the continuous evolution of antiretroviral therapy, leading to the development of more potent and tolerable treatments.

Furthermore, the intensified focus on extending treatment accessibility in low- and middle-income countries has contributed significantly to the market's expansion, as these regions shoulder a substantial portion of the global HIV burden.

This comprehensive market report encompasses a range of critical analyses, including patent assessment, grant evaluation, clinical trial scrutiny, funding and investment exploration, as well as an examination of partnerships and collaborations, all spearheaded by leading key players in the field.

Key Trends in the HIV Drugs Market

  • New antiretroviral drugs and regimens: The development of novel antiretroviral drugs and treatment regimens has improved treatment outcomes and reduced side effects, leading to better patient adherence and overall quality of life
  • Long-acting injectable therapies: The emergence of long-acting injectable HIV therapies has the potential to revolutionize treatment by reducing the burden of daily oral medication and improving treatment adherence
  • Expanding access to treatment: Global efforts to increase access to antiretroviral therapy in low- and middle-income countries have contributed to the growth of the HIV drugs market
  • Drug resistance and treatment optimization: Ongoing research focuses on addressing the issue of drug resistance, as well as optimizing treatment regimens to minimize side effects and maximize efficacy
  • Prevention strategies: The market is also witnessing growth in the demand for pre-exposure prophylaxis (PrEP) drugs, which are used to prevent HIV infection in high-risk individuals

Key Attributes:

Report AttributeDetails
No. of Pages160
Forecast Period2023 - 2031
Estimated Market Value (USD) in 2023$33.5 Billion
Forecasted Market Value (USD) by 2031$47.8 Billion
Compound Annual Growth Rate4.5%
Regions CoveredGlobal

The major companies in the market are as follows:

  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • GSK plc
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd
  • Mylan N.V
  • Sanofi
  • Bayer AG
  • ViiV Healthcare group of companies
  • Genentech, Inc

HIV Drugs Market Segmentations

Market Breakup by Drug Class

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Drugs
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors
  • Others

Market Breakup by Route of Administration


  • Tablets
  • Capsules


  • Intravascular
  • intramuscular
  • Others

Market Breakup by Drug Type

  • Branded
  • Generics

Market Breakup by End User

  • Hospitals
  • Clinics
  • Specialty Centers
  • Research Institutes
  • Others

Market Breakup by Distribution Channels

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global HIV Drugs Market

Contact Data